Crestor, the brand name for the drug rosuvastatin, is given to patients to lower blood cholesterol levels and to decrease the risk of heart attack and stroke. Crestor has recently been linked to serious health risks such as type II diabetes and liver damage. Crestor is the number two selling statin drug.
Crestor, one of the leading statin drugs, was released in 2003. It is used in children and adults to reduce the risk of strokes, heart attacks, and cardiovascular disease. Crestor’s sales have sky-rocketed, reaching global sales of $6.6 billion in 2011, a small portion of the more than $20 billion which is spent annually worldwide on statins. Crestor has grown in popularity as the population continues to suffer from unprecedented levels of diabetes, poor diet, and obesity. Crestor is effective for many consumers, but for others it can increase the risk of memory loss, type 2 diabetes, muscle pain, liver damage, and a muscle disease called rhabdomyolysis. Information concerning the risks of Crestor has been updated by the Food and Drug Administration.
In 2010, the FDA approved Crestor as another treatment option to for patients that have not necessarily had a cardiovascular event. For example, Crestor can now be used for patients who are at increased risk of heart disease but have not been diagnosed, men 50 years of age with elevated high sensitivity C-reactive protein and one other cardiovascular risk factor, women 60 years or older with elevated high sensitivity C-reactive protein in their blood and one other cardiovascular risk factor, or to slow the progression of atherosclerosis (a thickening of the artery wall caused by the build-up of cholesterol and other fatty materials within the blood).
According to the Internet Stroke Center, strokes are the the leading cause of serious, long-term disability in the United States. Each year close to 800,000 people have strokes, with most of them occurring in individuals over the age of sixty-five. Cardiovascular disease, including heart disease and strokes, are the leading cause of death in the United States. While many of these individuals have been treated for heart disease, many more are undiagnosed and not currently receiving proper medical treatment. Federal Officials report, however, there are more Americans taking cholesterol-lowering medications than ever before. In fact, according to the CDC, “The percentage of adults aged 40 and older taking drugs that combat high cholesterol rose from 20 percent to 28 percent between 2003 and 2012.” Currently, it’s estimated that 93% of the adults currently taking cholesterol lowering medications are using a statin. Despite risks of certain medications, such as Crestor, Medical experts continue to argue that statin therapy is one of the most effective, highly-valuable, preventative treatment options available, and statins continue to present an opportunity to further reduce death and disability due to heart disease and stroke.
Marketed by AstraZeneca, Crestor is part of a group of drugs referred to as HMG CoA reductase inhibitors, or statins. It helps users by reducing what experts refer to as “bad cholesterol” or the low-density lipoprotein and triglycerides in the blood, eliminating or reducing the slow build-up of plaque in a patient’s blood vessels (which can lead to heart issues and stroke).
Although the initial medical studies on the use of statins to treat cardiovascular issue was initially very promising, statins have recently come under fire. Some experts now warn that the earlier studies may not have been sufficient and did not fully examine some of the serious side-effects of statin use. New warnings include cautioning patients that statin use may increase their risk for liver injury, memory loss, diabetes, and muscle damage. Although the FDA has updated their warning about statin drugs, the FDA continues to maintain that statin’s benefits outweigh their potentially negative side-effects for most patients.